Education
About Us
Working with TipRanks
Follow Us
Syncom Formulation (India) Ltd. (IN:SYNCOMF)
:SYNCOMF
SYNCOMF Stock Chart & Stats
₹13.98
-₹0.26(-1.33%)
At close: 4:00 PM EST
₹13.98
-₹0.26(-1.33%)
Day’s Range― - ―
52-Week Range₹11.36 - ₹23.46
Previous CloseN/A
Volume2.15M
Average Volume (3M)249.72K
Market Cap
₹10.92B
Enterprise Value₹10.86B
Total Cash (Recent Filing)₹1.45B
Total Debt (Recent Filing)₹6.97M
Price to Earnings (P/E)17.7
Beta1.39
Next Earnings
May 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.20
Shares Outstanding940,000,000
10 Day Avg. Volume232,913
30 Day Avg. Volume249,719
Financial Highlights & Ratios
PEG Ratio0.27
Price to Book (P/B)4.34
Price to Sales (P/S)3.19
P/FCF Ratio110.11
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthAn 86% year-on-year revenue jump demonstrates strong demand traction and successful commercial execution. Durable top-line expansion supports better capacity utilization, scale economies and reinvestment in products and distribution, strengthening fundamentals over the next 2–6 months.
Margin Improvement & ProfitabilityImproved gross and net margins alongside healthy EBITDA indicate persistent operational efficiency gains. Sustainable margins provide a buffer against input cost volatility, enable reinvestment in quality/compliance and improve long-term free cash flow potential for the business.
Low Leverage And Strong Equity BaseExtremely low leverage and a high equity ratio reduce financial risk and preserve strategic optionality. This balance-sheet strength supports capital spending, potential market expansion or regulatory investments without heavy refinancing risk over the medium term.
Bears Say
Moderate Cash ConversionOperating cash converts to only ~47% of reported income and free cash flow swung from negative to positive recently, signaling cash volatility. This limits reliable internal funding for capex, working capital needs or distributions and heightens reliance on cash management execution.
Exposure To API Costs & Working CapitalMargins and cash flow are structurally sensitive to API price swings and inventory/receivable cycles. Such exposure can compress profitability and cash generation when commodity or supply-chain pressures persist, creating a recurring operational risk to earnings durability.
Limited Product/Partner DisclosureLack of granularity on product mix, customer concentration and partnerships reduces visibility into revenue sustainability and regulatory or market concentration risks. This information gap makes it harder to assess long-term growth quality and downside exposure.
Syncom Formulation (India) Ltd. News
SYNCOMF FAQ
What was Syncom Formulation (India) Ltd.’s price range in the past 12 months?
Syncom Formulation (India) Ltd. lowest stock price was ₹11.36 and its highest was ₹23.46 in the past 12 months.
What is Syncom Formulation (India) Ltd.’s market cap?
Syncom Formulation (India) Ltd.’s market cap is ₹10.92B.
When is Syncom Formulation (India) Ltd.’s upcoming earnings report date?
Syncom Formulation (India) Ltd.’s upcoming earnings report date is May 28, 2026 which is in 70 days.
How were Syncom Formulation (India) Ltd.’s earnings last quarter?
Syncom Formulation (India) Ltd. released its earnings results on Feb 12, 2026. The company reported ₹0.201 earnings per share for the quarter, beating the consensus estimate of N/A by ₹0.201.
Is Syncom Formulation (India) Ltd. overvalued?
According to Wall Street analysts Syncom Formulation (India) Ltd.’s price is currently Overvalued.
Does Syncom Formulation (India) Ltd. pay dividends?
Syncom Formulation (India) Ltd. pays a Notavailable dividend of ₹0.03 which represents an annual dividend yield of N/A. See more information on Syncom Formulation (India) Ltd. dividends here
What is Syncom Formulation (India) Ltd.’s EPS estimate?
Syncom Formulation (India) Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Syncom Formulation (India) Ltd. have?
Syncom Formulation (India) Ltd. has 940,000,000 shares outstanding.
What happened to Syncom Formulation (India) Ltd.’s price movement after its last earnings report?
Syncom Formulation (India) Ltd. reported an EPS of ₹0.201 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 0.282%.
Which hedge fund is a major shareholder of Syncom Formulation (India) Ltd.?
Currently, no hedge funds are holding shares in IN:SYNCOMF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Syncom Formulation (India) Ltd.
Syncom Formulations (India) Limited manufactures, markets, and sells pharmaceutical formulation products in India. It offers various products, including generics, alpha adrenoceptor agonists, analgesics, antipyretics, anti-inflammatory, anti-ulcer agents, antibiotics, antidepressants, antifungals, antihistamines, antimalarial, antiplatelet agents, antiprotozoal, antivirals, bronchodilators, calcium antagonists, cardiac medicines, central nervous stimulants, cephelo sporins, cortico steroids, estrogen, cough suppressants, erectile dysfunction, and electrolite. The company also provides histamines, homeostatic, hypoglycemic, hypolipidaemics, local anesthetics, multivitamins and nutritional supplements, sedative anticonvulsants, stimulants, and sympathomimetic products, as well as products used in the treatment of gout. In addition, it engages in the trading of commodities and renting of properties. Further, the company exports its products. It offers its pharmaceutical formulations products in various dosage forms, such as tablets, capsules, liquids orals, liquid vials, ampoule injections and dry vial injections, dry syrups, ointments, inhalers, and herbals. Syncom Formulations (India) Limited was founded in 1985 and is based in Indore, India.
Technical Analysis
GRP Ltd
―
Knowledge Marine & Engineering Works Limited
―
Media Matrix Worldwide Limited
―
Updater Services Limited
―
Uniparts India Ltd.
―